Biotech

All Articles

Despite mixed market, a financial backing resurgence might be being available in Europe: PitchBook

.While the biotech financial investment performance in Europe has slowed quite complying with a COVI...

8 months after a $213M fundraise, gene editor Volume produces cuts

.After bring up $213 thousand in 2023-- some of the year's largest exclusive biotech rounds-- Volume...

BioMarin builds director team along with biotech vets-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of considerable management hirings, firings and...

Biopharma Q2 VC struck highest degree since '22, while M&ampA reduced

.Equity capital financing in to biopharma cheered $9.2 billion around 215 deals in the second quarte...

Bicara, Zenas look for IPOs to press late-phase assets towards market

.Bicara Therapeutics and also Zenas Biopharma have delivered new impetus to the IPO market with fili...

Genentech to close cancer immunology research study team

.Genentech will close its own cancer immunology study department, and also device head as well as pr...

Kezar loses sound tumor yet to show its own well worth in stage 1 test

.Kezar Lifestyle Sciences is falling its unpromising period 1 sound growth drug as the biotech goes ...

Acelyrin loses izokibep, drops 3rd of workers

.Despite izokibep preserving its own newfound winning streak in the center, Acelyrin is actually no ...

Rivus' stage 2 obesity-related cardiac arrest test strikes endpoint

.Rivus Pharmaceuticals has actually plumped up the prospects of its own fat-busting, muscle-sparing ...

Ovid halts preclinical job, IV plan after soticlestat fall short

.Ovid Therapy presently disclosed final month that it was actually trimming back its head count as t...